The clinical utility of lung clearance index in early cystic fibrosis lung disease is not impacted by the number of multiple-breath washout trials

dc.contributor.authorFoong, Rachel E.
dc.contributor.authorHarper, Alana J.
dc.contributor.authorSkoric, Billy
dc.contributor.authorKing, Louise
dc.contributor.authorTurkovic, Lidija
dc.contributor.authorDavis, Miriam
dc.contributor.authorClem, Charles C.
dc.contributor.authorRosenow, Tim
dc.contributor.authorDavis, Stephanie D.
dc.contributor.authorRanganathan, Sarath
dc.contributor.authorHall, Graham L.
dc.contributor.authorRamsey, Kathryn A.
dc.contributor.departmentPediatrics, School of Medicineen_US
dc.date.accessioned2018-08-15T20:26:45Z
dc.date.available2018-08-15T20:26:45Z
dc.date.issued2018-02-16
dc.description.abstractThe lung clearance index (LCI) from the multiple-breath washout (MBW) test is a promising surveillance tool for pre-school children with cystic fibrosis (CF). Current guidelines for MBW testing recommend that three acceptable trials are required. However, success rates to achieve these criteria are low in children aged <7 years and feasibility may improve with modified pre-school criteria that accepts tests with two acceptable trials. This study aimed to determine if relationships between LCI and clinical outcomes of CF lung disease differ when only two acceptable MBW trials are assessed. Healthy children and children with CF aged 3-6 years were recruited for MBW testing. Children with CF also underwent bronchoalveolar lavage fluid collection and a chest computed tomography scan. MBW feasibility increased from 46% to 75% when tests with two trials were deemed acceptable compared with tests where three acceptable trials were required. Relationships between MBW outcomes and markers of pulmonary inflammation, infection and structural lung disease were not different between tests with three acceptable trials compared with tests with two acceptable trials. This study indicates that pre-school MBW data from two acceptable trials may provide sufficient information on ventilation distribution if three acceptable trials are not possible.en_US
dc.eprint.versionFinal published versionen_US
dc.identifier.citationFoong, R. E., Harper, A. J., Skoric, B., King, L., Turkovic, L., Davis, M., … Ramsey, K. A. (2018). The clinical utility of lung clearance index in early cystic fibrosis lung disease is not impacted by the number of multiple-breath washout trials. ERJ Open Research, 4(1), 00094–2017. http://doi.org/10.1183/23120541.00094-2017en_US
dc.identifier.urihttps://hdl.handle.net/1805/17148
dc.publisherEuropean Respiratory Societyen_US
dc.relation.isversionof10.1183/23120541.00094-2017en_US
dc.relation.journalERJ Open Researchen_US
dc.rightsAttribution-NonCommercial 3.0 United States
dc.rights.urihttp://creativecommons.org/licenses/by-nc/3.0/us/
dc.sourcePMCen_US
dc.subjectLung clearance indexen_US
dc.subjectCystic fibrosisen_US
dc.subjectMBW testingen_US
dc.subjectLCIen_US
dc.subjectCF lung diseaseen_US
dc.subjectMBW feasibilityen_US
dc.subjectVentilation distributionen_US
dc.subjectMultiple-breath washout trialsen_US
dc.titleThe clinical utility of lung clearance index in early cystic fibrosis lung disease is not impacted by the number of multiple-breath washout trialsen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
00094-2017.pdf
Size:
653.56 KB
Format:
Adobe Portable Document Format
Description:
Main article
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: